ACVR2B

(redirected from Activin receptor type IIB)

ACVR2B

A gene on chromosome 3p22 that encodes activin receptor type IIB, a receptor that forms a complex with other type-I and two type-II  transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. Type-I receptors are essential for signalling; type-II receptors are required for binding ligands and expression of type-I receptors. After activin binding, type-I receptors phosphorylate cytoplasmic SMAD transcription factors, which then translocate to the nucleus and interact directly with DNA or in complex with other transcription factors, playing roles in cell differentiation, growth arrest and apoptosis.
References in periodicals archive ?
surface receptor called activin receptor type IIB (ActRIIB).
CAMBRIDGE, Massachusetts, September 9, 2010 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB (ActRIIB) class of molecules being developed by Acceleron Pharma Inc.
ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through a cell surface receptor called activin receptor type IIB (ActRIIB).
CAMBRIDGE, Massachusetts, September 9, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB (ActRIIB) class of molecules being developed by Acceleron Pharma Inc.
This agreement grants Shire exclusive Ex-North American rights to Acceleron's ACE-031 molecule and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway.
a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway.
ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling through a cell surface receptor called activin receptor type IIB (ActRIIB).
ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
Treatment with a Form of Soluble Activin Receptor Type IIB Ameliorates the Effects of Estrogen Deficiency on Lean, Adipose and Bone Tissues" Date: Wednesday, June 10, 2009 Session Time: 11:15 am Room: 154AB, Walter E.
Treatment with a Soluble Activin Receptor Type IIB Prevents Androgen-Deprivation-Induced Effects on Muscle, Bone and Fat" Date: Friday, June 12, 2009 Session Time: 11:15 am Room: 144C, Walter E.